ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 709,75
0,00%
Dow Jones
43 487,83
0,78%
DAX
20 903,39
1,31%
Brent Oil
79,665
-0,69%
Bitcoin
102 501,62
1,48%
Registration Strip Icon for discussion Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ

  6. Amylyx Pharmaceuticals Inc (AMLX) Cours

Amylyx Pharmaceuticals Inc

Amylyx Pharmaceuticals Inc (AMLX)

NASDAQ
3,60
0,10
(2,86%)
Fermé 20 Janvier 10:00PM
Retardé de 15 minutes
3,61
0,01
(0,28%)
Après les heures de négociation: 12:56AM
Retardé de 15 minutes

Votre Hub pour des idées et discussions en direct en temps réel

Premium

Statistiques et détails clés

Dernier
3,61
Prix Achat
2,92
Prix Vente
4,67
Volume échangé
886 150
3,425 Fourchette du Jour 3,665
1,575 Plage de 52 semaines 19,9488
Cap du marché
247,458M
Clôture Veille
3,50
Ouverture
3,56
Dernière Transaction
34
@
3.63
Dernière heure de transaction
Volume financier
US$ 3 131 590
VWAP
3,5339
Volume moyen (3 m)
1 093 848
Actions en circulation
68 547 860
Rendement du Dividende
-
Ratio Cours sur Bénéfices
5,01
Bénéfice par action (BPA)
0,72
Chiffre d'affairess
380,79M
Bénéfice net
49,27M

À propos de Amylyx Pharmaceuticals Inc

Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases. Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases.

Secteur
Pharmaceutical Preparations
Industrie
Pharmaceutical Preparations
Site Web
www.amylyx.com
Siège social
Wilmington, Delaware, USA
Fondé
-
Amylyx Pharmaceuticals Inc est coté dans le secteur Pharmaceutical Preparations de la NASDAQ avec le ticker AMLX. Le dernier cours de clôture d'Amylyx Pharmaceuticals était de US$3,50. Au cours de la dernière année, les actions de Amylyx Pharmaceuticals ont été négociées dans une fourchette de prix de US$ 1,575 à US$ 19,9488.

Amylyx Pharmaceuticals compte actuellement 68 547 860 actions en circulation. La capitalisation boursière d'Amylyx Pharmaceuticals est de US$239,92 million. Amylyx Pharmaceuticals a un ratio cours/bénéfice (ratio PE) de 5.01.

AMLX Dernières nouvelles

Plus de nouvelles

Form 8-K - Current report

10 Janvier 2025
Edgar (US Regulatory)

Form 424B5 - Prospectus [Rule 424(b)(5)]

10 Janvier 2025
Edgar (US Regulatory)

Amylyx Pharmaceuticals Announces Pricing of Public Offering of Common Stock

Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced the pricing of an underwritten public offering of 17,142,857 shares of its common stock at a public...

10 Janvier 2025
Business Wire

Form 424B5 - Prospectus [Rule 424(b)(5)]

10 Janvier 2025
Edgar (US Regulatory)

Amylyx Pharmaceuticals Announces Proposed Public Offering of Common Stock

Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced that it has commenced an underwritten public offering of shares of its common stock. All of the shares are...

10 Janvier 2025
Business Wire

Form 4 - Statement of changes in beneficial ownership of securities

08 Janvier 2025
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

08 Janvier 2025
Edgar (US Regulatory)

Amylyx Pharmaceuticals Appoints Dan Monahan as Chief Commercial Officer

- Dan Monahan will lead the commercialization strategy across Amylyx’ product portfolio, beginning with avexitide, an investigational, first-in-class glucagon-like peptide-1 (GLP-1) receptor...

06 Janvier 2025
Business Wire

Form 8-K - Current report

30 Décembre 2024
Edgar (US Regulatory)

Amylyx Pharmaceuticals Announces Pivotal Phase 3 LUCIDITY Trial Design for GLP-1 Receptor Antagonist (Avexitide) in Post-Bariatric Hypoglycemia

- Pivotal Phase 3 LUCIDITY trial will evaluate FDA-agreed upon primary outcome of reduction in hypoglycemia events and designed to align as closely as possible with previous Phase 2 trial designs...

04 Décembre 2024
Business Wire
PériodeVariationVariation %Ouver.HautBasMoyenne Vol. Quot.VWAP
1-0.11-2.956989247313.723.793.0213102363.34490659CS
4-0.37-9.296482412063.984.183.027387523.62857599CS
12-1.29-26.32653061224.97.273.0210938485.00719407CS
261.2754.27350427352.347.271.7611756843.80167232CS
52-11.72-76.451402478815.3319.94881.57518319034.39117336CS
156-16.97-82.458697764820.5841.92971.575133443314.65006918CS
260-17.39-82.80952380952141.92971.575132958914.66886011CS

AMLX - Frequently Asked Questions (FAQ)

What is the current Amylyx Pharmaceuticals share price?
The current share price of Amylyx Pharmaceuticals is US$ 3,61
How many Amylyx Pharmaceuticals shares are in issue?
Amylyx Pharmaceuticals has 68 547 860 shares in issue
What is the market cap of Amylyx Pharmaceuticals?
The market capitalisation of Amylyx Pharmaceuticals is USD 239,92M
What is the 1 year trading range for Amylyx Pharmaceuticals share price?
Amylyx Pharmaceuticals has traded in the range of US$ 1,575 to US$ 19,9488 during the past year
What is the PE ratio of Amylyx Pharmaceuticals?
The price to earnings ratio of Amylyx Pharmaceuticals is 5,01
What is the cash to sales ratio of Amylyx Pharmaceuticals?
The cash to sales ratio of Amylyx Pharmaceuticals is 0,65
What is the reporting currency for Amylyx Pharmaceuticals?
Amylyx Pharmaceuticals reports financial results in USD
What is the latest annual turnover for Amylyx Pharmaceuticals?
The latest annual turnover of Amylyx Pharmaceuticals is USD 380,79M
What is the latest annual profit for Amylyx Pharmaceuticals?
The latest annual profit of Amylyx Pharmaceuticals is USD 49,27M
What is the registered address of Amylyx Pharmaceuticals?
The registered address for Amylyx Pharmaceuticals is 251 LITTLE FALLS DRIVE, WILMINGTON, DELAWARE, 19808
What is the Amylyx Pharmaceuticals website address?
The website address for Amylyx Pharmaceuticals is www.amylyx.com
Which industry sector does Amylyx Pharmaceuticals operate in?
Amylyx Pharmaceuticals operates in the PHARMACEUTICAL PREPARATIONS sector

Moteurs

Voir tout
  • Volume
  • % Gagnants
  • % Perdants
SymbolePrixVol.
BTCTBTC Digital Ltd
US$ 8,2697
(73,73%)
61,45M
BDMDBaird Medical Investment Holdings Ltd
US$ 8,80
(62,36%)
18,63M
CRKNCrown Electrokinetics Corporation
US$ 0,1235
(54,96%)
764,86M
NUKKNukkleus Inc
US$ 29,97
(45,98%)
19,09M
GSITGSI Technology
US$ 3,97
(44,36%)
87,7M
DOGZDogness International Corporation
US$ 18,23
(-58,77%)
740,45k
ORKTOrangeKloud Technology Inc
US$ 3,02
(-24,88%)
21,08M
PMAXPowell Max Ltd
US$ 0,6364
(-23,31%)
4,17M
LGCBLinkage Global Inc
US$ 0,2876
(-22,27%)
890,66k
YYAIConnexa Sports Technologies Inc
US$ 0,8299
(-20,20%)
602,48k
CRKNCrown Electrokinetics Corporation
US$ 0,1235
(54,96%)
764,86M
GCTKGlucoTrack Inc
US$ 0,0852
(15,45%)
465,22M
RIMEAlgorhythm Holdings Inc
US$ 0,0406
(-4,02%)
387,23M
TGLTreasure Global Inc
US$ 0,2459
(14,75%)
267,1M
NVDANVIDIA Corporation
US$ 137,71
(3,10%)
201,4M

Forums

Afficher les forums
Aucune Discussion Trouvée
Ajouter une Discussion

Dernières Valeurs Consultées

NASDAQ
AMLX
Amylyx Pharmaceuticals
NASDAQ
BTBD
BT Brands
COIN
TCTUSD
TokenClub
TSX
SPG
Spark Power
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2025 ADVFN PLC - Tous droits réservés